Evaluation of a novel tetra‐functional branched poly(ethylene glycol) crosslinker for manufacture of crosslinked, decellularized, porcine aortic valve leaflets
Source abstract
Abstract
To address concerns over limitations in the clinical use of glutaraldehyde (GA) fixation in bioprosthetic heart valves, we manufactured novel, branched poly(ethylene glycol) tetraacrylate (PEG‐TA) crosslinked valve leaflets and evaluated cytotoxic, thrombogenic, hemolytic, and anticalcification effects, thermal stability, and mechanical properties, in comparison to decellularized valves (control) and GA crosslinked valves. Thermal denaturation temperatures were higher for PEG‐TA valve leaflets compared to control and GA crosslinked valves (p < 0.001). Leaflet hydrolyzation rate was lower for the PEG‐TA group than for GA and control groups (p < 0.05). Superior cytocompatibility was found for PEG‐TA group leaflets (MTT,p < 0.01. apoptosis assay,p > 0.05). No thrombogenesis was found in platelet activation tests (p < 0.0001). Hemolysis assays showed that PEG‐TA leaflets would not cause damage to blood cells (p > 0.05). Excellent anticalcification properties were confirmed by von Kossa staining, western blot, and atomic absorption spectroscopy (p < 0.0001) in a rat subcutaneous embedding model. Finally, the novel PEG‐TA crosslinked material exhibits improved mechanical properties as compared to GA crosslinked materials (tensile strength,p < 0.001, Young's modulus,p < 0.001). On the basis of all results presented, it is clear that the performance characteristics of PEG‐TA crosslinked valve leaflets make PEG‐TA crosslinked leaflets a promising alternative for the next generation of bioprosthetic heart valve. © 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 102B: 322–336, 2014.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cardiac Valve Diseases and Treatments · Cardiac and Coronary Surgery Techniques · Electrospun Nanofibers in Biomedical Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Cardiovascular Surgery Union Hospital, Huazhong University of Science and Technology Wuhan 430022 China
School of Chemistry and Chemical Engineering Hubei University Wuhan Hubei 430062 China
References (45)
Show source-provided references
1. Heart disease and stroke statistics 2010 update: A report from the American Heart Association
2. 10.1146/annurev-bioeng-061008-12490310.1146/annurev-bioeng-061008-124903 ↗
3. 10.1007/s10439-006-9163-z10.1007/s10439-006-9163-z ↗
4. Choen FJ · 10
5. 10.1243/09544119JEIM23010.1243/09544119JEIM230 ↗
6. Tissue engineering of pulmonary heart valves on allogenic acellular matrix conduits: In vivo restoration of valve tissue
7. Tissue engineering of cardiac valve prostheses I: Development and histological characterization of an acellular porcine scaffold
8. Tissue engineering of cardiac valve prostheses II: Biomechanical characterization of decellularized porcine aortic heart valves
9. Construction of autologous human heart valves based on an acellular allograft matrix
10. 10.1016/j.biomaterials.2007.11.00710.1016/j.biomaterials.2007.11.007 ↗
11. 10.1016/S1010-7940(03)00094-010.1016/S1010-7940(03)00094-0 ↗
12. 10.1089/ten.2006.027910.1089/ten.2006.0279 ↗
13. 10.1016/S0142-9612(01)00235-610.1016/S0142-9612(01)00235-6 ↗
14. BaranskaA IrzykB SkiJN.Decellularized porcine valve scaffolds modified with carbodiimide for heart valve tissue engineering. The 34th Annual ESAO Congress Krems September 5–8 2007. Austria: Int J Artif Organs 2007.
15. Long term in vivo degradation and tissue response to photo‐cross‐linked elastomers prepared from star‐shaped prepolymers of poly(ε‐caprolactone‐co‐d,l‐lactide)10.1002/jbm.a.32422 ↗
16. 10.1529/biophysj.107.11101310.1529/biophysj.107.111013 ↗
17. 10.1016/j.athoracsur.2004.06.03310.1016/j.athoracsur.2004.06.033 ↗
18. 10.1016/j.biomaterials.2006.09.02910.1016/j.biomaterials.2006.09.029 ↗
19. 10.1016/S0022-5223(19)42561-010.1016/S0022-5223(19)42561-0 ↗
20. 10.1002/biot.20090021810.1002/biot.200900218 ↗
21. 10.1039/b920570p10.1039/b920570p ↗
22. 10.1158/1078-0432.CCR-09-280410.1158/1078-0432.CCR-09-2804 ↗
23. 10.1002/jbm.b.3095210.1002/jbm.b.30952 ↗
24. 10.1016/j.bmc.2004.07.04110.1016/j.bmc.2004.07.041 ↗
25. 10.1023/A:102038020349910.1023/A:1020380203499 ↗
26. 10.1002/pol.1984.17022020710.1002/pol.1984.170220207 ↗
27. 10.1161/01.CIR.95.2.47910.1161/01.CIR.95.2.479 ↗
28. 10.1016/0142-9612(95)92125-P10.1016/0142-9612(95)92125-P ↗
29. 10.1159/00008373010.1159/000083730 ↗
30. 2011
31. 10.1161/CIRCRESAHA.109.21370210.1161/CIRCRESAHA.109.213702 ↗
32. 10.1074/jbc.M31409820010.1074/jbc.M314098200 ↗
33. 10.1007/s10439-011-0256-y10.1007/s10439-011-0256-y ↗
34. 10.1016/j.jmmm.2011.08.04310.1016/j.jmmm.2011.08.043 ↗
35. 10.1016/S0022-5223(19)42988-710.1016/S0022-5223(19)42988-7 ↗
36. Recellularization of heart valve grafts by a process of adaptive remodeling
37. 10.1007/s00018-008-8498-z10.1007/s00018-008-8498-z ↗
38. 10.1089/ten.2006.12.205910.1089/ten.2006.12.2059 ↗
39. 10.1016/j.biomaterials.2007.11.00710.1016/j.biomaterials.2007.11.007 ↗
40. 10.1016/j.carpath.2010.04.00610.1016/j.carpath.2010.04.006 ↗
41. 10.1002/jps.2081310.1002/jps.20813 ↗
42. 10.1046/j.1365-2036.2003.01390.x10.1046/j.1365-2036.2003.01390.x ↗
43. 10.1002/(SICI)1097-4636(199610)32:2<209::AID-JBM9>3.0.CO;2-X10.1002/(SICI)1097-4636(199610)32:2<209::AID-JBM9>3.0.CO;2-X ↗
44. 10.1161/01.CIR.102.18.226210.1161/01.CIR.102.18.2262 ↗
45. 10.1517/14712598.4.12.197110.1517/14712598.4.12.1971 ↗